Accenture shares are down around 15% in pre-market trading following the publication of its Q2 2026 results. Although the company beat market expectations on earnings per share and delivered a full-year outlook better than consensus, the stock is falling.
The negative investor reaction was mainly triggered by a series of large acquisitions in the cybersecurity sector. The market is currently bearish on cybersecurity, assuming that further AI development will make the industry lose its relevance.
Earnings
- Revenue came in at $18.7bn, below the consensus of about $18.8bn, but still 6% higher y/y.
- EPS was $3.80 versus $3.72 expected.
- New bookings totaled $19.3bn, compared with $19.7bn a year earlier.
- Operating margin increased by 20 basis points to 17.0%.
Guidance
- The company now expects full-year EPS of $13.78-$13.90, versus market expectations of $13.80.
- Accenture also expects FY 2026 revenue growth of 3-4%.
- Free cash flow guidance was maintained at $10.8-$11.5bn.
Controversial purchases
The transactions announced alongside the results drew the most market attention. Accenture announced plans to acquire a majority stake in Dragos and to acquire runZero and NetRise in full.
The combined enterprise value of these transactions is about $4.17bn. Closing is expected in August or September 2026, subject to regulatory approvals.
Accenture’s management presents these deals as a strategic strengthening of its position in operational technology security (OT Security). CEO Julie Sweet said the acquisitions are intended to increase the company’s market share and create a new growth platform.
The market, however, sees the purchases mainly as short-term pressure on results and large spending on a sector viewed as lacking strong prospects. Integration of the new businesses into the company’s operations is also being questioned.
Context
ACN.US (D1)
From a valuation perspective, the company has not had a good period. It is now trading close to the valuation levels seen at the bottom of the sell-off during the market’s reaction to the COVID-19 pandemic. From its peak, the company has lost more than 70% in valuation, and 40% in valuation this year alone. Importantly, profits and profitability do not indicate a decline or a significant loss of growth momentum. The company has reached a P/E of 13 and a price-to-sales ratio of 1.4. Source: xStation5.
Morning Wrap – Market Returns to Normalcy After Hawkish Fed Forecasts and a Mixed Warsh (11.08.2026)
Daily Summary - Oil Nearly Erases War Gains as Wall Street Pulls Back Ahead of Fed Decision (16.06.2026)
US OPEN: SpaceX pushes Amazon off the TOP 5 podium. Wall Street awaits Warsh's debut
OpenAI heads into a price war ahead of an IPO?
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.